We have discovered a biological axis, Mib2‐Runx2‐Hmgcs2, in the regulation of cardiac steatosis in HFpEF, providing a promising therapeutic strategy for cardiometabolic HFpEF. This evidence concerns the gene RUNX2 and steatosis.